Seattle Genetics Inc., the first company to gain FDA approval for an antibody-drug conjugate, has licensed rights to a breast cancer ADC that has been designated a potential breakthrough therapy. Seattle will pay $250 million up front to Immunomedics Inc. for global rights to sacituzumab govitecan (IMMU-132). Immunomedics can earn development, regulatory and sales-based milestone payments up to $1.7 billion, along with tiered double-digit royalties. Seattle also purchased a 2.8% equity stake in Immunomedics and can buy 8.7 million additional shares in the company through an unspecified date. [See Deal]
Sarepta Therapeutics Inc. has sold the voucher it received upon approval of its Duchenne muscular dystrophy treatment Exondys 51...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?